

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

Date: - 08/11/2023

To,

Department of Corporate Services, BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street. Mumbai - 400 001 SCRIP CODE: 530843

The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051 Fax No. - 6641 8125 / 26 SCRIP CODE: CUPID

Subject: - Outcome of Board Meeting and Financial Results for Quarter ended 30th September, 2023

Dear Sir / Madam.

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting and Financial Results for quarter and half year ended 30th September, 2023 pursuant to regulation 30 and regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 respectively.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors

For Cupid Limited

+91 2551 230280 / 230772

+91 7722009580

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:



A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India CIN No.: L25193MH1993PLC070846

www.cupidlimited.com

info@cupidlimited.com



We Help The World Dlay Safe

CUPID LIMITED Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

OUTCOME OF BOARD MEETING

November 8th, 2023:

The Board of Directors of the Cupid Limited at its meeting held on November 8th, 2023, inter alia, had considered and approved the following matters: -

Commencement time of Board Meeting: - 5.30 P.M.

Conclusion time of Board Meeting: - 6.05 P.M.

- Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for quarter ended 30th September, 2023 were considered and reviewed by the Board.
- 2. Unaudited Financial Results for quarter and half year ended 30th September, 2023 were considered and adopted by the Board. (Financial Results as attached)

Place: - Mumbai Date: - 08/11/2023 By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:

C

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India



+91 2551 230280 / 230772 +91 7722009580



CIN No.: L25193MH1993PLC070846

 Partners :
 Sohan Chaturvedi
 FCA

 Chaturvedi V N
 FCA

 Noshir B Captain
 FCA

 Rajiv Chauhan
 ACA

 Neha Chauhan
 ACA

 Shristi Chaturvedi
 ACA

 Prakash Mistry
 FCA



Chaturvedi Sohan & Co.

Chartered Accountants

FRN - 118424W

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Limited Review Report to The Board of Directors CUPID LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of Cupid Ltd (the "Company") for the quarter and half year ended September 30, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board, of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with standards on Auditing specifies under section 143(10) of the Act. We have not performed an audit and accordingly, we do not express an audit opinion.

320, Tulsiani Chambers, Nariman Point, Mumbai 400 021. India. Tel: +91 22 2281 5154 /56, +91 9022 952550 E-Mail:-accounts@cachaturvedi.com / audit@cachaturvedi.com /tax@cachaturvedi.com /finance@cachaturvedi.com website: www.cachaturvedi.com 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi Sohan & eo. Chartered Accountants FRN: 118424W

Vivekanand Chaturved Partner Membership No.106403 UDIN: 23106403BGPOUF8029

MUMBAL 21

Place: Mumbai Date:08-11-2023.

Cupid Limited

CIN No : L25193MH1993PLC070846

Regd. Office :- A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India. Ph:- 02551-230280, Fax:- 02551-230279, Website: www.eupidlimited.com, Email- info@cupidlimited.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended 30th September, 2023

		(Quarter Ended (the second se	acs except EPS Half Yea	and the second sec	Year Ended on
S.No.	Particulars	30-Sep-2023 (Unaudited)	30-Jun-2023 (Unaudited)	30-Sep-2022 (Unaudited)	30-Sep-2023 (Unaudited)	30-Sep-2022 (Unaudited)	31-Mar-2023 (Audited)
1	Revenue from operation	3,446.37	3,367.60	4,524.94	6,813.97	7,606.56	15,932.72
2	Other Non - operation Incomes	198.60	152.17	95.57	350.77	162.82	476.97
	Total Income	3,644.97	3,519.77	4,620.51	7,164.74	7,769.38	16,409.69
3	Expenses						
a)	Cost of Material Consumed	1,524.86	1,187.28	2,017.20	2,712.14	3,636.26	6,572.9
b)	Change in Inventories	(742.05)	(6.07)	(272.81)	(748.12)	(418.10)	(71.68
c)	Employee benefit expenses	390.27	487.57	295.98	877.84	581.66	1,376.8
d)	Finance costs	7.51	40.32	6.47	47.83	14.27	78.8
e)	Depreciation	72.25	71.40	70.90	143.65	136.11	296.9
f)	Other Expenses	1,750.58	1,516.70	1,284.55	3,267.28	2,028.22	3,924.1
	Total Expenses	3,003.43	3,297.20	3,402.29	6,300.63	5,978.42	12,177.7
4	Profit from Continuing Operation Before Exceptional items and Taxes	641.54	222.57	1,218.22	864.11	1,790.96	4,231.9
5	Profit From Ordinanry Activities Before Tax	641.54	222.57	1,218.22	864.11	1,790.96	4,231.90
6 a) b) c)	Less : Tax Expenses Income tax for current quarter/ year Short / (Excess) provision of earlier years Deferred Tax Expenses / (Credit)	128.96 - 0.97	88.18 - (81.40)	325.71 - 34.55	217.14 - (80.43)	496.67 (27.11)	1,022.07
7	Net Profit / (Loss) From Ordinanry Activities after tax for the period	511.61	215.79	857.96	727.40	1,321.40	3,158.2
8	Other Comprehensive Income / (Loss) (Net of Tax)						
a)	Item that will not be reclassified to profit and loss account						
(i)	Remeasurement of employee defined benefit obligation	44.39	•	-	44.39	•	(16,4)
	Income Tax relating to items that will not be reclassified to profit or loss	(11.17)			(11.17)		4,1
9	Total Comprehensive Income (after tax) for the period	478.39	215.79	857.96	694.18	1,321.40	3,145.9
10	Paid up Equity Share Capital (Face value Rs.10/-)	1,333.80	1,333.80	1,333.80	1,333.80	1,333.80	1,333.8
n	Earning Per Share (EPS) (* Not Annualised)						
(a)	Basic EPS (Amount is ₹)	3.84*	1.62*	6.43*	5.45*	9.91*	23.68
(b)	Diluted EPS (Amount is ₹)	3.81*	1.61*	6,43*	541*	9.91*	23.



NOTES TO THE QUARTERLY RESULT: -

- The above financial results have been reviewed and recommended for approval by the Audit Committee to the Board of Directors and have been approved by the Board of Director at its meeting held on 8th November, 2023.
- Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principle of lnd AS notified under the Companies (Indian Accounting Standard) Rules, 2015 as amended from time to time.
- 3. The company's business operation comprises of operating segments viz., Male and Female contraceptives, other relevant products and In Vitro Devices (IVD).
- The Board of Directors authorised Mr. Aditya Halwasiya, Managing Director to sign the standalone financial results of the company for quarter ended 30th Sep, 2023.
- 5. During quarter ended 30th September, 2023, the Company has transferred unpaid and unclaimed dividend of Rs. 4,94,282 to IEPF.
- The previous period / year financial figures have been regrouped / rearranged wherever necessary to make them comparable.
- The results of the Company are available for investors at https://www.cupidlimited.com/, https://www.nseindia.com/ and https://www.bseindia.com/

Place: Mumbai Date: 8th November, 2023 For and on behalf of Board of Director of Cupid Limited

Afaliousing

Aditya Halwasiya Managing Director



Particulars	As at	Lacs except EPS) As at
1 al ticulars	30.09.2023	31.03.2023
	Unaudited	Audited
ASSETS		
Non-current assets	1000	
Property, Plant and Equipment	3,586.53	3,600.97
Capital Work In Progress	-	
Intangible assets	9.17	4.79
Financial Non - Current Assets		
Non Current Investments		
Other financial assets		
Other non-current assets		
Total Non - Current Assets	3,595.69	3,605.76
Current assets	1.1.1	
Inventories	2,700.99	1,910.45
Financial Current Assets		
Trade receivables	2,427.85	2,564.27
Current Investments	6,553.26	6,933.18
Cash and cash equivalents	83.75	30.05
Bank balances other than cash & cash equivalents	4,741.21	2,931.57
Short Term Loan	67.90	61.54
Other financial assets	215.97	107.45
Other current assets	810.97	738.75
Total Current Assets	17,601.90	15,277.26
Total Assets	21,197.59	18,883.03
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	1,333.80	1,333.80
Other Equity	15,780.47	15,378.54
Total Equity	17,114.27	16,712.34
LIABILITIES		
Non-current liabilities	1142	
Deferred tax liabilities (net)	42.71	134.30
Provisions	•	20.52
Total Non Current Liabilities	42.71	154.82
Current liabilities	74.71	134.84
Financial Current Liabilities		
Current Borrowings	935.96	597.49
Trade payables	755.70	397.49
i) Total Outstanding dues of Micro, Small and Medium Enterprises		2.00
	1 102 50	3.00
ii) Total Outstanding dues of Vendors other than above Other financial liabilities	1,102.59	870.15 221.88
Provisions	127.86	
Other current liabilities		53.59
Income tax liabilities (Net)	396.30	238.91
Total Current Liabilities	4,040.62	30.86 2,015.88
Total Fauity and Liabilities		
Total Equity and Liabilities	21,197.59	18,883.03

Cupid Limited

Statement of Assets and Liabilities as at September, 30, 2023

Stahreisigen

Cupid Limited Statement of Cash flows

Dortionlore	1 1 30 00 2023	(Rs. In Lacs)
Particulars Operating activities	As at 30.09.2023	As at 31.03.2023
Net Profit/(Loss) before Tax	064.11	
Net FIGHU(Loss) before Tax	864.11	4,231.90
Adjustments to reconcile profit before tax to net cash inflow from opera	ting activities	
Finance Cost	47.83	78.82
Depreciation	143.65	296.93
Unrealised (Income)/loss on Mutual Fund	(61.97)	(32.63)
Interest Income	(254.35)	(414.06)
OCI	(33.21)	(12.35)
ESOP Reserve	107.88	81.39
Expected credit loss	4.11	(358.57)
	818.05	3,871.43
Working capital adjustments:-		
(Increase) / Decrease in Inventories	(790.54)	(125.49)
(Increase) / Decrease in Other Loans and advances	(6.36)	522.21
(Increase) / Decrease in Other current assets	(180.74)	207.09
(Increase) / Decrease in Trade and other Receivables	132.31	605.64
Increase / (Decrease) in Provision	53.75	(34.36)
Increase / (Decrease) in Trade Payables	229.44	(342.32)
Increase / (Decrease) in Other Current Liabilities & Provisions	1,413.41	(335.39)
	1669.33	4,368.81
Income taxes paid	(259.17)	(1,097.70)
Net cash flow from operating activities (A)	1,410.16	3,271.11
Investing activities		
Purchase of property, plant and equipment	(133.58)	(254.37)
(Increase) / Decrease in fixed deposit	(1,809.64)	(825.09)
(Purchase)/Sale of Investments & Fair Value Changes	441.89	(1,524.78)
Interest Income	254.35	414.06
Sale of Fixed Assets		4.01
Net cash flow used in investing activities (B)	(1,246.98)	(2,186.17)
Financing activities		
Dividend Paid	(400.12)	(733.59)
Short Term Borrowings	338.47	(282.24)
Interest paid	(47.83)	(78.82)
Net cash flow from financing activities (C)	(109.48)	(1,094.65)
the clish how hom manening activities (c)	(10).40)	(1,094.03)
Increase in cash and cash equivalents (A+B+C)	53.70	(9.71)
Cash and cash equivalents at the beginning of the year	30.05	39.77
Cash and cash equivalents at the end of the period	83.75	30.05

Note: - The above cashflow has been prepared under Indirect Method as set out in Ind AS 7 "Statement of Cash Flows"



Philinge 9

		Ouarter Ended On		Half Vear Ended	r Ended	Van Fedad an
Particular	30-Sep-2023	30-Jun-2023	30-Sep-2022	30-Sep-2023	30-Sep-2022	31-Mar-2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						(
a) Male and Female Contraceptives & Jelly	3,360.02	3,352.62	4,521.42	6.712.64	7.602.90	15.892.48
b) In Vitro Devices (IVD)	86.36	14.98	3.52	101.34	3.66	40.23
c) Others / Unallocated	198.60	152.17	95.57	350.77	162.82	476.98
Total	3,644.98	3,519.77	4.620.51	7.164.74	82 092 2	16 409 60
Less: Inter Segment Revenue		1		-	normal to	C0*C0+'01
Gross Revenue from sale of product & Service	3,644.98	3,519.77	4,620.51	7.164.74	7.769.38	16.409.69
2 Segment Results Profit/(Loss) Before Tax						
a) Male and Female Contraceptives & Jelly	474.46	103.92	1.140.20	578.38	1 700 81	3 807 86
b) In Vitro Devices (IVD)	(31.52)	(33.52)	(17.55)	(65.04)	(72.67)	(142.94)
c) Others / Unailocated	198.60	152.17	95.57	350.77	162.82	476.98
Total Profit Before Tax	641.54	222.57	1,218.22	864.11	1,790.96	4,231.90
3 Segment Assets a) Male and Female Contraceptives & Jelly	7,923.90	6,521.73	7,966.71	7.923.90	7.966.71	7.390.09
b) In Vitro Devices (IVD)	806.82	822.31	730.94	806.82	730.94	721.90
c) Others / Unallocated	12,466.87	11,774.24	10,364.93	12,466.87	10,364.93	10,613.68
Total Assets	21,197.59	19,118.28	19,062.59	21,197.59	19,062.59	18,725.67
4 Segment Liabilities						
a) Male and Female Contraceptives & Jelly	4,053.71	1,459.33	2,668.88	4.053.71	2.668.88	1 616 16
b) Vitro Diagnostic Device (IVD)	122.05	22.08	672.07	122 05	20.000	58.00
c) Others / Unallocated	832.47	189.47	672.07	832.47	672.07	338.28
Total Liabilities	5 000 3	00 047 1	101200			

Alemening